TransCode Therapeutics Makes Progress in RNA Cancer Therapy Trial
TL;DR
TransCode Therapeutics advances to Phase 1b dose expansion stage for RNA-based cancer therapeutic with promising early PK/PD data.
TransCode Therapeutics dosed the third patient in Cohort 4 of Phase 1a trial for TTX-MC138, with expanded enrollment and stable disease seen.
TransCode Therapeutics aims to defeat cancer through intelligent RNA therapeutics design, potentially unlocking access to novel genetic targets for treating various cancers.
TransCode Therapeutics' TTX-MC138 shows target engagement with no significant toxicities, offering hope for improved cancer treatments and expanding therapeutic possibilities.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has reported significant progress in its Phase 1a clinical trial of TTX-MC138, an innovative RNA-based cancer therapeutic targeting metastatic tumors. The company has now treated 15 patients across four different dose levels, with the Safety Review Committee approving expanded enrollment and noting no significant toxicities or disease progression.
The trial's early pharmacokinetic and pharmacodynamic data suggest promising target engagement, potentially marking a breakthrough in addressing metastatic cancers that overexpress microRNA-10b. Ten patients remain actively enrolled in the study, with the longest-treated patient demonstrating stable disease after seven treatment cycles.
This development is particularly noteworthy for the oncology community, as it represents a potential advancement in treating hard-to-manage metastatic cancers. By focusing on RNA therapeutics delivered through a proprietary nanoparticle platform, TransCode is exploring an innovative approach to cancer treatment that could offer new hope for patients with aggressive, treatment-resistant tumors.
The successful completion of this phase sets the stage for advancing to the Phase 1b dose expansion stage, which could provide more comprehensive insights into the therapeutic potential of TTX-MC138. The company's approach of targeting specific genetic markers represents a precision medicine strategy that could revolutionize cancer treatment methodologies.
Curated from InvestorBrandNetwork (IBN)
